Clindamycin for the treatment of infections: the influence of rifampicin and obesity on PK/PD target attainment

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515872-12-00

Acronym

S65747

Enrollment

Registered

2025-01-14

Start date

2025-07-29

Completion date

Unknown

Last updated

2025-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fracture related infections, Hidradenitis suppurativa, Prosthetic joint infections

Brief summary

Pharmacokinetic parameters (AUC, Vd, Clearance, Elimination half-life)

Detailed description

Effectiveness of treatment, Clinical cure

Interventions

DRUGRIFAMPICIN

DRUGCLINDAMYCIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Pharmacokinetic parameters (AUC, Vd, Clearance, Elimination half-life)	—

Secondary

Measure	Time frame
Effectiveness of treatment, Clinical cure	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026